Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (A021502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized, Double-Blinded, Controlled Study of ONT- 380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (ONT-380-206) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients who Smoke Cigarettes (A221401)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Registry for Lung Screening Excellence
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Single Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic GU Cancers (SGN22E-001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Comparing Rovalpituzumab Tesirine Vs Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemo III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Comparing Tislelizumab + Platinum And Fluoropyrimidine Versus Placebo Plus Platinum And Fluoropyrimidine As First-Line Treatment In Patients With Locally Advanced Unresectable Or Metastatic Gastric or GEJ Adenocarcinoma (BGBA317- 305) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy (11282 SGN35-015) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer (I5B-MC-JGDP) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress1) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer; (AFT-19) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Of Concurrent Durvalumab And Radiation Therapy Followed By Adjuvant Durvalumab In Patients With Urothelial Cancer (T2-4 N0-2 M0) Of The Bladder (BTCRC GU15-023) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of FOLFIRINOX plus Ramucirumab versus FOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients (GI14-198) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Of High Dose Interleukin 2 Vs High Dose Interleukin 2 Plus Entinostat In Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of mFolfox6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatci Colorectal Cancer (GI004) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low Blast Acute Myelogenous Leukemia(Pevonedistat-3001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (N0577) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Testing the Addition of Nivolumab Pre and Post Nephrectomy in Patients with Renal Cell Carcinoma (EA8143) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (CONNECT) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Thyroid Cancer Registry (463-07)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members